PTK2 and neoplasm: From a translational standpoint, this suggests that therapeutic strategies should avoid directly targeting caspase activation and instead intervene at downstream effectors, such as blocking PGE2/FAK or NF-κB pathways to redirect signaling toward anti-tumor outcomes while minimizing pro-tumor escape routes.